Navellier & Associates Inc Exelixis, Inc. Transaction History
Navellier & Associates Inc
- $705 Million
- Q3 2024
A detailed history of Navellier & Associates Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Navellier & Associates Inc holds 22,070 shares of EXEL stock, worth $765,608. This represents 0.08% of its overall portfolio holdings.
Number of Shares
22,070Holding current value
$765,608% of portfolio
0.08%Shares
5 transactions
Others Institutions Holding EXEL
# of Institutions
503Shares Held
244MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.16 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.02 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$881 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$533 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$397 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.2B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...